Duke Perspectives from the 2021 American Society of Hematology Annual Meeting

Duke Perspectives from the 2021 American Society of Hematology Annual Meeting

PDF Publication
Continue to Course
Online Course | Specialties: Hematology
Released: 1/17/2022
Expires: 7/16/2022
Max Credits: 0.5
Continue to Course Read Abstract

Harry P. Erba, MD, PhD
Professor of Medicine
Director, Leukemia Program
Duke University School of Medicine
Durham, NC

Activity Planners
Julie Blum, PhD
Director, Clinical Content
Baltimore, MD
Lisa R. Rinehart, MS, ELS
Director, Editorial Services
Baltimore, MD
Samantha Gordon, MS
Accreditation Manager
Baltimore, MD
Amy Sison
Director of CME
Baltimore, MD

Katherine Kahn
Holyoke, MA
Learning Objective
Upon completion, participants should be able to:

  • Discuss pertinent new studies presented at ASH and consider how to apply this information to clinical practice

Target Audience
This activity is intended for hematologists.
Statement of Need
More than 90 presentations were shared by faculty members, residents, and fellows from the Duke University School of Medicine, Department of Hematology at the 2021 ASH Annual Meeting. Herein, we summarize information from select presentations and provide expert insight from Harry Erba, MD, PhD, director of the Leukemia Program and director of Phase I Development in Hematologic Malignancies at Duke University School of Medicine, with the goal of helping local and community hematologists and internists stay abreast of current clinical research taking place at Duke Hematology.

Collaboration Statement
This activity was developed by Med-IQ in collaboration with Duke Health.

Accreditation Statement
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medium/Method of Participation
This CME activity consists of a 0.5-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly. 

Initial Release Date: January 17, 2022
Expiration Date: July 16, 2022
Estimated Time to Complete This Activity: 30 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all financial relationships with any ineligible company over the past 24 months. The ACCME deems financial relationships as relevant if the educational content an individual can control is related to the business lines or products of the ineligible company. Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and mitigate COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

Off-label/unapproved drug uses or products are mentioned within this activity.

Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been mitigated through an established COI mitigation process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 

Harry P. Erba, MD, PhD
Consulting fees/advisory boards: AbbVie Inc., Agios Pharmaceuticals, Astellas Pharma US, Inc., Bristol-Myers Squibb, Celgene Corporation, Daiichi Sankyo, Co., Ltd., GlycoMimetics, Inc., ImmunoGen, Inc., Incyte Corporation, Jazz Pharmaceuticals, Kura Oncology, MacroGenics, Novartis Pharmaceuticals Corporation, Pfizer, Inc., Servier, Syros Pharmaceuticals, Inc., Takeda Pharmaceuticals North America, Inc., Trillium Therapeutics, Inc.
Fees received for promotional/non-CME activities: AbbVie Inc., Agios Pharmaceuticals, Bristol-Myers Squibb, Celgene Corporation, Incyte Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation, Servier
Contracted research: AbbVie Inc., ALX Oncology, Amgen, Ascentage Pharma, Daiichi Sankyo, Co., Ltd., Forma Therapeutics, Forty-Seven, Inc., Gilead Sciences, GlycoMimetics, Inc., ImmunoGen, Inc., Jazz Pharmaceuticals, Kura Oncology, MacroGenics, Novartis Pharmaceuticals Corporation, PTC Therapeutics

The writer, peer reviewers, and activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information       
For questions or comments about this activity, please contact Med-IQ.
Call (toll-free) 866 858 7434 or e-mail

System Requirements



  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy notice, please visit:

© 2022 Duke University Health System 


Developed in collaboration

Here are the key takeaways from this activity. Deeper insights and evidence, plus an opportunity to receive credit, are available at the "Continue" button below.

  • HSCT with omidubicel results in rapid hematopoietic recovery, reduced rates of infections, and no increase in graft-versus-host disease rates compared with standard UCB transplantation1
  • The MDM2 protein inhibitor siremadlin in combination with venetoclax is safe and effective in the treatment of R/R AML and high-to-very high-risk MDS2
  • Preliminary results of the CPX-351 plus venetoclax arm of the V-FAST trial indicate that time to neutrophil recovery (≥ 500/µL) was 36 days for 18 to 59 age group and 33.5 days for the 60 to 75 age group; the median time to platelet recovery (≥ 50,000/µL) was 36.5 days for the 18 to 49 age group and 30.5 days for the 60 to 75 age group3
  • An open-label, multicenter trial examining the safety and efficacy of IMGN632 as part of a triplet regimen with azacitidine and venetoclax in patients with R/R CD123-positive AML showed higher response rates in patients who received either a higher dose of 45 µg/kg or those receiving 14 or 21 days of venetoclax; ORR was 48% with the triplet regimen, with a composite CR of 30%4
  • Results from phase 1 of the ASPEN-02 study that investigated the safety and efficacy of evorpacept in combination with azacitidine in high-risk MDS showed that evorpacept plus azacitidine is safe and well tolerated in patients with MDS; evorpacept demonstrated promising activity in multiple subgroups of patients with MDS with poor prognosis, including those with prior HMA failure, therapy-related MDS, and TP53 mutations associated with complex cytogenetic abnormalities5
  • Results of a phase 2 study that evaluated the feasibility of combining the TKI dasatinib with prednisone and blinatumomab for the treatment of older patients with Ph+ or Ph-like ALL showed that OS at 3 years is predicted to be 85% (95% CI, 58% to 95%); the Kaplan-Meier estimate of DFS at 3 years was predicted to be 80% (95% CI, 55% to 92%)6

View reference list.

Click “Continue” to proceed through this activity and/or receive credit. 

By clicking "Continue," you confirm that you have reviewed the CME information.


Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

COPYRIGHTED. Republication or redistribution of Med‑IQ content, including by framing, is prohibited without prior written consent. Med‑IQ shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.